Despite recent clinical trials showing the therapeutic potential of inhibiting renin-angiotensin-aldosterone system (RAS) and sodium-glucose cotransporter-2 (SGLT2) in slowing the progression of CKD [3,4], there is still a high incidence of end-stage renal disease (ESRD). This evidence concerns the gene SLC5A2 and stage 5 chronic kidney disease.